Neuroscience

Pioneering brain and nervous system research

Brain & Nervous System Research

SXR Laboratories specializes in neuroscience trials for neurological and psychiatric disorders. Our expertise spans neurodegenerative diseases, mental health conditions, and pain management.

Research Areas

Alzheimer’s and dementia studies
Parkinson’s disease trials
Depression and anxiety research
Epilepsy treatment studies
Multiple sclerosis trials
Chronic pain management

Foundational Technologies & Key Targets

Molecular Targets

Amyloid-beta & Tau: Pathological proteins in Alzheimer’s disease targeted by monoclonal antibodies to reduce plaque formation and neurofibrillary tangles.

Alpha-synuclein: Misfolded protein aggregates in Parkinson’s disease, targeted to prevent neurodegeneration.

Huntingtin (HTT): Mutant protein causing Huntington’s disease, targeted by ASOs and gene editing.

SOD1: Superoxide dismutase 1, implicated in ALS (Amyotrophic Lateral Sclerosis), targeted by antisense oligonucleotides.

Therapeutic Modalities

ASOs (Antisense Oligonucleotides): Gene silencing technology used successfully in Spinal Muscular Atrophy and under investigation for Huntington’s disease. Monoclonal Antibodies (mAbs): Targeting amyloid plaques in Alzheimer’s disease. Small Molecules: Traditional drugs crossing the blood-brain barrier for various CNS conditions.

Gene Therapy Applications

CRISPR Gene Editing: Exploring correction of mutant Huntingtin gene to halt disease progression. AAV Vector Delivery: Using adeno-associated virus to deliver therapeutic genes for rare neurological disorders, including lysosomal storage diseases affecting the CNS. RNAi (RNA Interference): Silencing disease-causing genes in hereditary neurodegenerative conditions.

Specialized Assessments

We employ comprehensive neurological assessments including cognitive testing, neuroimaging, biomarker analysis, and patient-reported outcomes to evaluate treatment efficacy and safety.

Integrated Research Excellence

Neuroscience research requires specialized expertise across interconnected services. Clinical Trials Management coordinates complex cognitive assessments and neuroimaging protocols across multiple sites. Data Management expertly handles intricate cognitive scale data and biomarker results, while Biostatistics applies sophisticated methodologies for neurodegenerative disease progression analysis. Regulatory Affairs navigates the unique challenges of CNS drug development and patient-reported outcomes. Medical Writing translates complex neurological findings into clear regulatory documents, and Quality Assurance ensures the reliability of sensitive cognitive and behavioral data.